Navigation Links
Ikaria® to Present at 2011 Wedbush Life Sciences Management Access Conference
Date:8/9/2011

HAMPTON, N.J., Aug. 9, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2011 Wedbush Life Sciences Management Access Conference on Tuesday, August 16, 2011 at 1:50 p.m. EDT in the Gamshoge room at Le Parker Meridien.  The conference will be held August 16-17 in New York, NY.

About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings.  Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ikaria® Names New Chief Financial Officer
2. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
3. Ikaria® Launches Next-Generation Drug-Delivery System
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... PARK, Calif. , Nov. 17, 2014 ... company in the emerging field of regenerative medicine, today ... President of Research and Development, will participate in a ... for Regenerative Medicine (CIRM) discussing the latest progress in ... The CIRM Google Hangout session is scheduled for ...
(Date:11/17/2014)... Wilson Therapeutics AB, a development stage biopharmaceutical company, ... study to evaluate efficacy and safety of its lead ... disorder and designated orphan disease, in which the body ... delighted to proceed with this important clinical study in ... development program for WTX101," said David Clark , ...
(Date:11/17/2014)... 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: INO ... their 2013 collaboration, option, and license agreement to co-develop ... as their research collaboration in prostate cancer. All of ... the product to other parties, will be returned to ... phase I clinical trial in the first half of ...
Breaking Medicine Technology:Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 3Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 2Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 3Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 4Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 5
... NEW YORK, June 2, 2011 Citeline, the world,s ... recently completed a comprehensive review of clinical trial starts ... patterns in drug development. Over the one-year review period ... trials were initiated in the oncology sector, more than ...
... Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today ... Trademark Office of Patent Application Serial No. 12/549458 ... This follows the UK issuance which was granted ... patent estate. The patent covers the ...
Cached Medicine Technology:Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 2Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 3Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat 2Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat 3
(Date:11/17/2014)... A Diet Doc in-house clinical study ... are turning back the clock on aging, looking younger ... the company has recently added their prescription anti-aging human ... prescription and non-prescription diet products and healthy living supplements. ... best anti-aging human growth hormone therapy to their ...
(Date:11/17/2014)... Oskaloosa, IA (PRWEB) November 17, 2014 ... featured in an upcoming episode of American Farmer airing ... Tuesday at 8:30 am ET on RFD-TV. , World ... organic plant based proteins. World Food’s unique system provides ... seed to protein ingredients. , This segment will educate ...
(Date:11/17/2014)... (PRWEB) November 17, 2014 QuickChek customers ... their September “Dog Tag” Promotion. In total, ... Hope For The Warriors® in support of military families ... is a national nonprofit dedicated to restoring a sense ... for our service members and our military families. ...
(Date:11/17/2014)... (PRWEB) November 17, 2014 For the ... specialist used DNA sequencing from a single cell extracted ... that ran in the father’s family. Double-board certified expert ... Springs and Newport Beach, then implanted only the healthy ... , “The world of In Vitro Fertilization has taken ...
(Date:11/17/2014)... (PRWEB) November 17, 2014 Wright & ... Miami ordered Boston Scientific Corp. to pay a total ... who filed bladder mesh lawsuits after they suffered injuries ... company’s Pinnacle transvaginal mesh implant. Bloomberg reported that jurors ... defectively designed and the company failed to warn physicians ...
Breaking Medicine News(10 mins):Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3Health News:American Farmer to Feature World Food Processing in 2015 Series 2Health News:QuickChek Gives Big Support to Hope For The Warriors One Dollar at a Time 2Health News:IVF Specialist From American Reproductive Centers Performs World's First DNA Sequencing On Single Cell So Defected Genes Won't Be Passed To Future Generations 2Health News:Boston Scientific Ordered To Pay $28.7 Million In Bladder Mesh Lawsuits After Injuries From Pelvic Mesh Implant Reports Wright & Schulte LLC 2Health News:Boston Scientific Ordered To Pay $28.7 Million In Bladder Mesh Lawsuits After Injuries From Pelvic Mesh Implant Reports Wright & Schulte LLC 3Health News:Boston Scientific Ordered To Pay $28.7 Million In Bladder Mesh Lawsuits After Injuries From Pelvic Mesh Implant Reports Wright & Schulte LLC 4
... Feb. 1 (HealthDay News) -- Among injection drug users, new ... two decades, but the number of new infections from the ... new study reports. The findings suggest that efforts -- ... to prevent blood-borne transmission of infectious diseases have been successful ...
... February 1, 2011 While the overall death rate for ... to have higher death rates and shorter survival of any ... The findings come from Cancer Facts & Figures for African ... two years by the American Cancer Society. The higher ...
... circulating DNA may indicate faster progression of lung cancer ... in the February edition of the Journal of ... Association for the Study of Lung Cancer (IASLC). ... presented more free DNA in the blood than healthy ...
... , MONDAY, Jan. 31 (HealthDay News) -- X-rays, CT scans ... back pain, but often these tests are unnecessary, suggests new ... more, these imaging tests have the potential to cause harm ... -- such as a bulging disc -- that may not ...
... Steven Reinberg HealthDay Reporter , MONDAY, Jan. 31 ... having a stroke, they appear to have better odds of ... This finding might seem odd since conventional wisdom says black ... medical care in general. However, the same trend has been ...
... services that supports California,s low-income, disabled elderly is fragile, ... independent lives in their own homes, according to a ... Research. This policy note reports the ... lives and challenges encountered by several dozen representative older ...
Cached Medicine News:Health News:Infectious Disease Experts Call for More Focus on Hepatitis C 2Health News:Race gap narrows for some cancers in African-Americans; continues to increase for others 2Health News:Race gap narrows for some cancers in African-Americans; continues to increase for others 3Health News:High levels of circulating DNA may signal faster progression of lung cancer 2Health News:Most X-Rays, Scans Unnecessary for Acute Low Back Pain 2Health News:Most X-Rays, Scans Unnecessary for Acute Low Back Pain 3Health News:Survival After Stroke Better for Blacks 2Health News:Survival After Stroke Better for Blacks 3Health News:Aging safely at home? California's disabled elderly are barely holding on 2Health News:Aging safely at home? California's disabled elderly are barely holding on 3
... The Vitros 250 is ... meet requirements in multiple environments ... large hospitals, clinics and satellite ... features on-board dilution, and can ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
Medicine Products: